Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:

(a) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.

As of December 31, 2022 and 2021, commercial license and other economic rights consist of the following (in thousands):

(1) Amounts represent accumulated amortization to principal of $11.6 million and credit loss adjustments of $6.5 million as of December 31, 2022.

(2) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021.

Royalty revenue for 2022, 2021 and 2020 for continuing operations are reported as below (in thousands):

The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):

(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.

The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):


	Year Ended December 31,
	2022	2021	2020
Weighted average shares outstanding:	16,868	16,630	16,185
Dilutive potential common shares:
Restricted stock	—	96	56
Stock options	—	520	584


Shares used to compute diluted income per share	16,868	17,246	16,825
Potentially dilutive shares excluded from calculation due to anti-dilutive effect	6,241	4,793	8,458